Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Synthetic modeling reveals HOXB genes are critical for the initiation and maintenance of human leukemia.

Kusakabe M, Sun AC, Tyshchenko K, Wong R, Nanda A, Shanna C, Gusscott S, Chavez EA, Lorzadeh A, Zhu A, Hill A, Hung S, Brown S, Babaian A, Wang X, Holt RA, Steidl C, Karsan A, Humphries RK, Eaves CJ, Hirst M, Weng AP.

Nat Commun. 2019 Jul 2;10(1):2913. doi: 10.1038/s41467-019-10510-8.

2.

Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study.

Rousseau F, Langlois S, Johnson JA, Gekas J, Bujold E, Audibert F, Walker M, Giroux S, Caron A, Clément V, Blais J, MacLeod T, Moore R, Gauthier J, Jouan L, Laporte A, Diallo O, Parker J, Swanson L, Zhao Y, Labelle Y, Giguère Y, Forest JC, Little J, Karsan A, Rouleau G.

Eur J Hum Genet. 2019 Jun 23. doi: 10.1038/s41431-019-0443-0. [Epub ahead of print]

PMID:
31231136
3.

Genomic testing in myeloid malignancy.

Docking TR, Karsan A.

Int J Lab Hematol. 2019 May;41 Suppl 1:117-125. doi: 10.1111/ijlh.13022. Review.

PMID:
31069982
4.

Endothelial Sash1 Is Required for Lung Maturation through Nitric Oxide Signaling.

Coulombe P, Paliouras GN, Clayton A, Hussainkhel A, Fuller M, Jovanovic V, Dauphinee S, Umlandt P, Xiang P, Kyle AH, Minchinton AI, Humphries RK, Hoodless PA, Parker JDK, Wright JL, Karsan A.

Cell Rep. 2019 May 7;27(6):1769-1780.e4. doi: 10.1016/j.celrep.2019.04.039.

5.

Fixation Effects on Variant Calling in a Clinical Resequencing Panel.

Parker JDK, Yap SQ, Starks E, Slind J, Swanson L, Docking TR, Fuller M, Zhou C, Walker B, Filipenko D, Xiong W, Karimuddin AA, Phang PT, Raval M, Brown CJ, Karsan A.

J Mol Diagn. 2019 Jul;21(4):705-717. doi: 10.1016/j.jmoldx.2019.03.005. Epub 2019 May 2.

PMID:
31055024
6.

Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.

Thibodeau ML, Zhao EY, Reisle C, Ch'ng C, Wong HL, Shen Y, Jones MR, Lim HJ, Young S, Cremin C, Pleasance E, Zhang W, Holt R, Eirew P, Karasinska J, Kalloger SE, Taylor G, Majounie E, Bonakdar M, Zong Z, Bleile D, Chiu R, Birol I, Gelmon K, Lohrisch C, Mungall KL, Mungall AJ, Moore R, Ma YP, Fok A, Yip S, Karsan A, Huntsman D, Schaeffer DF, Laskin J, Marra MA, Renouf DJ, Jones SJM, Schrader KA.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003681. doi: 10.1101/mcs.a003681. Print 2019 Apr.

7.

A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.

Pandoh PK, Corbett RD, McDonald H, Alcaide M, Kirk H, Trinh E, Haile S, MacLeod T, Smailus D, Bilobram S, Mungall AJ, Ma Y, Moore RA, Coope R, Zhao Y, Jones SJ, Holt RA, Karsan A, Morin RD, Marra MA.

Biotechniques. 2019 Feb;66(2):85-92. doi: 10.2144/btn-2018-0148.

8.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

9.

A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.

Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD.

J Mol Diagn. 2019 Mar;21(2):214-227. doi: 10.1016/j.jmoldx.2018.09.007. Epub 2018 Nov 23.

PMID:
30472330
10.

High-Resolution Single-Cell DNA Methylation Measurements Reveal Epigenetically Distinct Hematopoietic Stem Cell Subpopulations.

Hui T, Cao Q, Wegrzyn-Woltosz J, O'Neill K, Hammond CA, Knapp DJHF, Laks E, Moksa M, Aparicio S, Eaves CJ, Karsan A, Hirst M.

Stem Cell Reports. 2018 Aug 14;11(2):578-592. doi: 10.1016/j.stemcr.2018.07.003. Epub 2018 Aug 2.

11.

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a003327. doi: 10.1101/mcs.a003327. Print 2018 Aug. No abstract available.

12.

Non-invasive prenatal aneuploidy testing: Critical diagnostic performance parameters predict sample z-score values.

Blais J, Giroux S, Caron A, Clément V, Dionne-Laporte A, Jouan L, Gauthier J, MacLeod T, Moore R, Parker J, Swanson L, Zhao Y, Rouleau G, Karsan A, Langlois S, Rousseau F.

Clin Biochem. 2018 Sep;59:69-77. doi: 10.1016/j.clinbiochem.2018.06.015. Epub 2018 Jun 27.

13.

miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.

Lam J, van den Bosch M, Wegrzyn J, Parker J, Ibrahim R, Slowski K, Chang L, Martinez-Høyer S, Condorelli G, Boldin M, Deng Y, Umlandt P, Fuller M, Karsan A.

Nat Commun. 2018 Jun 20;9(1):2418. doi: 10.1038/s41467-018-04831-3.

14.

Applications of Bayesian network models in predicting types of hematological malignancies.

Agrahari R, Foroushani A, Docking TR, Chang L, Duns G, Hudoba M, Karsan A, Zare H.

Sci Rep. 2018 May 3;8(1):6951. doi: 10.1038/s41598-018-24758-5.

15.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

16.

CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.

Cremin C, Howard S, Le L, Karsan A, Schaeffer DF, Renouf D, Schrader KA.

Hered Cancer Clin Pract. 2018 Mar 7;16:7. doi: 10.1186/s13053-018-0088-y. eCollection 2018.

17.

An actionable test using loss of heterozygosity in identifying high-risk oral premalignant lesions.

Liu KYP, Lu XJD, Cheng YL, Klieb H, Ng S, McNeil K, Karsan A, Poh CF.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Dec 18. pii: S2212-4403(17)31208-7. doi: 10.1016/j.oooo.2017.10.019. [Epub ahead of print]

PMID:
29428696
18.

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.

Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.

Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.

19.

Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform.

Chang KTE, Goytain A, Tucker T, Karsan A, Lee CH, Nielsen TO, Ng TL.

J Mol Diagn. 2018 Jan;20(1):63-77. doi: 10.1016/j.jmoldx.2017.09.007. Epub 2017 Nov 20.

20.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

21.

APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.

Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, Fuller M, Gibb EA, Wei W, Huntsman DG, Karsan A, Hoodless PA.

Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.

PMID:
29079036
22.

Meis2 as a critical player in MN1-induced leukemia.

Lai CK, Norddahl GL, Maetzig T, Rosten P, Lohr T, Sanchez Milde L, von Krosigk N, Docking TR, Heuser M, Karsan A, Humphries RK.

Blood Cancer J. 2017 Sep 29;7(9):e613. doi: 10.1038/bcj.2017.86.

23.

Detection and genomic characterization of a mammary-like adenocarcinoma.

Grewal JK, Eirew P, Jones M, Chiu K, Tessier-Cloutier B, Karnezis AN, Karsan A, Mungall A, Zhou C, Yip S, Tinker AV, Laskin J, Marra M, Jones SJM.

Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a002170. doi: 10.1101/mcs.a002170. Print 2017 Nov.

24.

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer.

Hout DR, Schweitzer BL, Lawrence K, Morris SW, Tucker T, Mazzola R, Skelton R, McMahon F, Handshoe J, Lesperance M, Karsan A, Saltman DL.

Cancers (Basel). 2017 Aug 1;9(8). pii: E99. doi: 10.3390/cancers9080099.

25.

Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR).

Lebo MS, Zakoor KR, Chun K, Speevak MD, Waye JS, McCready E, Parboosingh JS, Lamont RE, Feilotter H, Bosdet I, Tucker T, Young S, Karsan A, Charames GS, Agatep R, Spriggs EL, Chisholm C, Vasli N, Daoud H, Jarinova O, Tomaszewski R, Hume S, Taylor S, Akbari MR, Lerner-Ellis J; Canadian Open Genetics Repository Working Group.

Genet Med. 2018 Mar;20(3):294-302. doi: 10.1038/gim.2017.80. Epub 2017 Jul 20.

PMID:
28726806
26.

Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada.

Goy J, Gillan TL, Bruyere H, Huang SJT, Hrynchak M, Karsan A, Ramadan K, Connors J, Toze CL, Gerrie AS.

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):382-389. doi: 10.1016/j.clml.2017.04.001. Epub 2017 May 8.

PMID:
28559149
27.

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Weymann D, Laskin J, Roscoe R, Schrader KA, Chia S, Yip S, Cheung WY, Gelmon KA, Karsan A, Renouf DJ, Marra M, Regier DA.

Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.

28.

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, J Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, J Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001628. doi: 10.1101/mcs.a001628. Print 2017 Sep. Erratum in: Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):.

29.

Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.

Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS.

Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524. Epub 2017 Apr 27. Review.

30.

Assembling draft genomes using contiBAIT.

O'Neill K, Hills M, Gottlieb M, Borkowski M, Karsan A, Lansdorp PM.

Bioinformatics. 2017 Sep 1;33(17):2737-2739. doi: 10.1093/bioinformatics/btx281.

31.

Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications.

Foroushani A, Agrahari R, Docking R, Chang L, Duns G, Hudoba M, Karsan A, Zare H.

BMC Med Genomics. 2017 Mar 16;10(1):16. doi: 10.1186/s12920-017-0253-6.

32.

Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada.

Huang SJ, Bergin K, Smith AC, Gerrie AS, Bruyere H, Dalal CB, Sugioka DK, Hrynchak M, Ramadan KM, Karsan A, Gillan TL, Toze CL.

Cancer Genet. 2017 Jan;210:1-8. doi: 10.1016/j.cancergen.2016.10.006. Epub 2016 Nov 3.

PMID:
28212806
33.

Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.

Huang SJ, Lee LJ, Gerrie AS, Gillan TL, Bruyere H, Hrynchak M, Smith AC, Karsan A, Ramadan KM, Jayasundara KS, Toze CL.

Leuk Res. 2017 Apr;55:79-90. doi: 10.1016/j.leukres.2017.01.023. Epub 2017 Jan 15.

PMID:
28157628
34.

Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V.

Am J Clin Pathol. 2016 Oct;146(4):408-22. doi: 10.1093/ajcp/aqw131. Review.

PMID:
27686169
35.

Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing.

Parker JD, Shen Y, Pleasance E, Li Y, Schein JE, Zhao Y, Moore R, Wegrzyn-Woltosz J, Savage KJ, Weng AP, Gascoyne RD, Jones S, Marra M, Laskin J, Karsan A.

Cold Spring Harb Mol Case Stud. 2016 Mar;2(2):a000679. doi: 10.1101/mcs.a000679.

36.

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.

Laskin J, Jones S, Aparicio S, Chia S, Ch'ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, Huntsman D, Jones M, Kasaian K, Karsan A, Leelakumari S, Li Y, Lim H, Ma Y, Mar C, Martin M, Moore R, Mungall A, Mungall K, Pleasance E, Rassekh SR, Renouf D, Shen Y, Schein J, Schrader K, Sun S, Tinker A, Zhao E, Yip S, Marra MA.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570.

37.

Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia.

Cressman S, Karsan A, Hogge DE, McPherson E, Bolbocean C, Regier DA, Peacock SJ.

Br J Haematol. 2016 Aug;174(4):526-35. doi: 10.1111/bjh.14076. Epub 2016 Apr 21.

38.

Initial Diagnosis of ALK-Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR.

Lund HL, Hughesman CB, Fakhfakh K, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster LJ, Haynes C.

Anal Chem. 2016 May 3;88(9):4879-85. doi: 10.1021/acs.analchem.6b00707. Epub 2016 Apr 12.

PMID:
27043019
39.

Estimating deep molecular responses in chronic myelogenous leukemia: a Bayesian approach.

Young SS, Tucker T, Bosdet I, Karsan A.

Leukemia. 2016 Jul;30(7):1628-9. doi: 10.1038/leu.2016.37. Epub 2016 Mar 8. No abstract available.

PMID:
26952806
40.

Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay.

Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won JR, Wolber R, Bryan J, Hughesman C, Haynes C.

J Mol Diagn. 2016 Mar;18(2):190-204. doi: 10.1016/j.jmoldx.2015.09.003. Epub 2016 Jan 4.

PMID:
26762843
41.

Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.

Lund HL, Hughesman CB, McNeil K, Clemens S, Hocken K, Pettersson R, Karsan A, Foster LJ, Haynes C.

Anal Bioanal Chem. 2016 Feb;408(4):1079-94. doi: 10.1007/s00216-015-9204-2. Epub 2015 Dec 2.

PMID:
26631023
42.

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.

Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski JP, Meetei RA, Inoue J, Starczynowski DT.

J Exp Med. 2015 Oct 19;212(11):1967-85. doi: 10.1084/jem.20141898. Epub 2015 Oct 12.

43.

Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada.

Huang SJ, Gillan TL, Gerrie AS, Hrynchak M, Karsan A, Ramadan K, Smith AC, Toze CL, Bruyere H.

Genes Chromosomes Cancer. 2016 Jan;55(1):16-24. doi: 10.1002/gcc.22294. Epub 2015 Sep 22.

PMID:
26391112
44.

MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.

Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, Heuser M, Hogge D, Camargo FD, Engelhardt S, Döhner H, Buske C, Jongen-Lavrencic M, Naldini L, Humphries RK, Kuchenbauer F.

Exp Hematol. 2015 Oct;43(10):858-868.e7. doi: 10.1016/j.exphem.2015.05.018. Epub 2015 Jul 8.

45.

A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation.

Patenaude A, Woerher S, Umlandt P, Wong F, Ibrahim R, Kyle A, Unger S, Fuller M, Parker J, Minchinton A, Eaves CJ, Karsan A.

Microvasc Res. 2015 Sep;101:38-47. doi: 10.1016/j.mvr.2015.05.004. Epub 2015 Jun 17.

PMID:
26092680
46.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.

Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11.

47.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. doi: 10.1016/j.clml.2014.12.015. Epub 2015 Jan 3.

PMID:
25656914
48.

Deep profiling of multitube flow cytometry data.

O'Neill K, Aghaeepour N, Parker J, Hogge D, Karsan A, Dalal B, Brinkman RR.

Bioinformatics. 2015 May 15;31(10):1623-31. doi: 10.1093/bioinformatics/btv008. Epub 2015 Jan 18.

49.

Kleat: cleavage site analysis of transcriptomes.

Birol I, Raymond A, Chiu R, Nip KM, Jackman SD, Kreitzman M, Docking TR, Ennis CA, Robertson AG, Karsan A.

Pac Symp Biocomput. 2015:347-58.

50.

Loss of the Notch effector RBPJ promotes tumorigenesis.

Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A.

J Exp Med. 2015 Jan 12;212(1):37-52. doi: 10.1084/jem.20121192. Epub 2014 Dec 15.

Supplemental Content

Loading ...
Support Center